These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 24029229)

  • 1. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
    Leung-Hagesteijn C; Erdmann N; Cheung G; Keats JJ; Stewart AK; Reece DE; Chung KC; Tiedemann RE
    Cancer Cell; 2013 Sep; 24(3):289-304. PubMed ID: 24029229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
    Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC
    Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
    Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
    Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why proteasome inhibitors cannot ERADicate multiple myeloma.
    Orlowski RZ
    Cancer Cell; 2013 Sep; 24(3):275-7. PubMed ID: 24029222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
    Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH
    Blood; 2006 Jun; 107(12):4907-16. PubMed ID: 16507771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
    Iida S; Ri M
    Rinsho Ketsueki; 2014 Mar; 55(3):304-10. PubMed ID: 24681933
    [No Abstract]   [Full Text] [Related]  

  • 7. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
    Wada N; Kawano Y; Fujiwara S; Kikukawa Y; Okuno Y; Tasaki M; Ueda M; Ando Y; Yoshinaga K; Ri M; Iida S; Nakashima T; Shiotsu Y; Mitsuya H; Hata H
    Int J Oncol; 2015 Mar; 46(3):963-72. PubMed ID: 25530098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATF6 upregulates XBP1S and inhibits ER stress-mediated apoptosis in osteoarthritis cartilage.
    Guo FJ; Xiong Z; Lu X; Ye M; Han X; Jiang R
    Cell Signal; 2014 Feb; 26(2):332-42. PubMed ID: 24269637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
    Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
    Nishimura N; Radwan MO; Amano M; Endo S; Fujii E; Hayashi H; Ueno S; Ueno N; Tatetsu H; Hata H; Okamoto Y; Otsuka M; Mitsuya H; Matsuoka M; Okuno Y
    Cancer Sci; 2019 Oct; 110(10):3275-3287. PubMed ID: 31368616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
    Lee AH; Iwakoshi NN; Anderson KC; Glimcher LH
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9946-51. PubMed ID: 12902539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoplasmic reticulum stress in malignancy.
    Clarke HJ; Chambers JE; Liniker E; Marciniak SJ
    Cancer Cell; 2014 May; 25(5):563-73. PubMed ID: 24823636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
    Gu JL; Li J; Zhou ZH; Liu JR; Huang BH; Zheng D; Su C
    Biochem Biophys Res Commun; 2012 Apr; 420(3):644-50. PubMed ID: 22450313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B; Li J; Mao X
    Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
    Xu X; Liu J; Huang B; Chen M; Yuan S; Li X; Li J
    Tumori; 2017 May; 103(3):261-267. PubMed ID: 27647225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and development of second-generation proteasome inhibitors.
    Kirk CJ
    Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unfolded protein response.
    Cao SS; Kaufman RJ
    Curr Biol; 2012 Aug; 22(16):R622-6. PubMed ID: 22917505
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation.
    Zhang D; De Veirman K; Fan R; Jian Q; Zhang Y; Lei L; Evans H; Wang Y; Lei L; Wang B; Williamson RA; Chantry A; He P; Li A; De Raeve H; Vanderkerken K; He A; Hu J
    Stem Cell Res Ther; 2020 Nov; 11(1):516. PubMed ID: 33256835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
    Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.